MedPath

Anlotinib

Generic Name
Anlotinib
Drug Type
Small Molecule
Chemical Formula
C23H22FN3O3
CAS Number
1058156-90-3
Unique Ingredient Identifier
GKF8S4C432

Overview

Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.

Indication

用于治疗非小细胞肺癌、结直肠癌、肾癌、软组织肉瘤、甲状腺癌、胃癌等。 用于无法手术的局部晚期或转移性甲状腺髓样癌患者的治疗。

Associated Conditions

No associated conditions information available.

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/06/25
Phase 2
Recruiting
JIANYANG WANG
2025/06/17
Phase 2
Recruiting
First Affiliated Hospital of Zhejiang University
2025/06/08
Phase 4
Not yet recruiting
Fujian Medical University
2025/05/14
Phase 1
Recruiting
2025/04/30
Phase 4
Not yet recruiting
2025/04/17
Phase 4
Not yet recruiting
2025/02/28
Phase 2
Recruiting
Sun Yat-sen University
2025/01/07
Phase 2
Not yet recruiting
2024/12/18
Phase 2
Recruiting
Tianjin Medical University Second Hospital
2024/11/21
Phase 2
Not yet recruiting

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Anlotinib Hydrochloride Capsules
国药准字H20180002
化学药品
胶囊剂
4/17/2023
Anlotinib Hydrochloride Capsules
国药准字H20180004
化学药品
胶囊剂
4/17/2023
Anlotinib Hydrochloride Capsules
国药准字H20180003
化学药品
胶囊剂
4/17/2023

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.